Revive Therapeutics (RVVTF) announced that it has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute. The researcher aims to investigate Bucillamine’s potential as a cancer treatment, particularly for boosting anti-tumor effects in patients with advanced solid tumors. This evaluation of Bucillamine in solid tumors would be integrated into a broader study, supported by funding from the NIH and/or other government entities. This proposed research builds on our strategy of evaluating novel uses of Bucillamine in academic and government supporting studies, including the partnership with Defence R&D Canada – Suffield Research Centre, an agency of the Canadian Department of National Defence, evaluating Bucillamine as a potential treatment for nerve agent exposure. Results from this study are expected shortly.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVVTF:
- Revive Therapeutics Expands Pipeline with Molecular Hydrogen Acquisition
- Revive enters asset purchase agreement for molecular hydrogen program
- Revive Therapeutics Aligns with Shareholders in Annual Meeting Decisions
- Revive Therapeutics announces results of annual shareholder meeting
- Revive Therapeutics to Acquire DiagnaMed’s Molecular Hydrogen Program for Neurological Treatments